Scott Smith Net Worth
The estimated Net Worth of Scott Andrew Smith is at least $2.31 Thousand dollars as of 28 June 2019. Mr. Smith owns over 12,000 units of Titan Pharmaceuticals stock worth over $2,306 and over the last 5 years he sold TTNP stock worth over $0. In addition, he makes $0 as Director at Titan Pharmaceuticals.
Mr. Smith TTNP stock SEC Form 4 insider trading
Scott has made over 23 trades of the Titan Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 12,000 units of TTNP stock worth $49,080 on 28 June 2019.
The largest trade he’s ever made was buying 12,000 units of Titan Pharmaceuticals stock on 28 June 2019 worth over $49,080. On average, Scott trades about 2,551 units every 28 days since 2014. As of 28 June 2019 he still owns at least 13,883 units of Titan Pharmaceuticals stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Scott Smith biography
Scott A. Smith serves as Director of the Company. He has served in various management capacities with Celgene Corporation since 2008, including as President, Inflammation and Immunology since August 2014. From 2003 to 2008, he served in various executive capacities with Biovail Pharmaceuticals, Inc. and prior thereto spent 16 years Pharmacia & Upjohn Company. Mr. Smith holds a BSc in Chemistry and Biology and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters in International Management from the American Graduate School of International Management in Arizona.
How old is Scott Smith?
Scott Smith is 55, he’s been the Director of Titan Pharmaceuticals since 2017. There are 7 older and no younger executives at Titan Pharmaceuticals. The oldest executive at Titan Pharmaceuticals, Inc. is Eurelio Cavalier, 82, who is the Independent Director.
What’s Scott Smith’s mailing address?
Scott’s mailing address filed with the SEC is C/O SPRING BANK PHARMACEUTICALS, INC., 35 PARKWOOD DRIVE, HOPKINTON, MA, 01748.
Insider trading at Titan Pharmaceuticals
Over the last 4 years, insiders at Titan Pharmaceuticals have traded over $0 worth of Titan Pharmaceuticals stock and bought 968,967 units worth $587,921 . The most active insider traders include James R Mcnab, Marc Rubin, and Joseph A Akers. On average, Titan Pharmaceuticals executives and independent directors trade stock every 102 days with the average trade being worth of $14,631. The most recent stock trade was executed by James R Mcnab on 21 September 2018, trading 200,000 units of TTNP stock currently worth $50,000.
What does Titan Pharmaceuticals do?
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in development of therapeutics for the treatment of medical disorders. Its products include Probuphine, Ropinirole Implant, and T3 Implant. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
What does Titan Pharmaceuticals’s logo look like?
Complete history of Mr. Smith stock trades at Celgene, Spring Bank Pharmaceuticals, and Titan Pharmaceuticals
Titan Pharmaceuticals executives and stock owners
Titan Pharmaceuticals executives and other stock owners filed with the SEC include:
- Sunil Bhonsle, President, Director
- Marc Rubin, Executive Chairman of the Board
- James McNab, Independent Director
- M. David MacFarlane, Independent Director
- Eurelio Cavalier, Independent Director
- Joseph Akers, Independent Director
- Scott Smith, Director
- Federico Seghi Recli, Director
- Rajinder Kumar, Director
- Seghi Recli, Lead Director
- Dane Hallberg, Executive Vice President and Chief Commercial Officer
